

5AV +806

PATENT /6 4

8-21-98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Habib Zaghouani)	Group Art Unit 1806
Serial No. Filed	:	08/779,767 January 7, 1997))	I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on July 15, 1998
For	:	Compounds, Compositions, and Methods For The Endocytic)	
		Presentation of Immunosuppressive Factors)	Christopher A. Dayton, Reg. No. 35,114
Examiner	:	J. Reeves) _)	•

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

ALLIA.143A

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the mailing date of a final office action under 37 C.F.R. § 1.113 and before the mailing date of a notice of allowance under Section 1.311. A certification under 37 C.F.R. §1.97 (e) (2) is set forth below. Thus, no fee is required as set forth in 37 C.F.R. §1.97 (c).

The undersigned certifies that each item of information contained within this Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement.

JUL 2 3 1998

MATON CENTRAL

Serial No.

08/779,767

Filed

January 7, 1997

Applicants respectfully solicit the Examiner's consideration of the cited references and entry thereof into the record of this application.

Respectfully submitted,

ALLIANCE PHARMACEUTICAL CORP.

Dated: 15 July 1998

Christopher A. Dayton

Registration No. 35,114

Attorney of Record

143sup.doc